Accelerate Diagnostics Inc. (NASDAQ:AXDX) traded with a subtraction of -$0.02 to close at $0.61 on Friday, a downside of -2.93 percent. An average of 498,418 shares of common stock have been traded in the last five days. There was a gain of $0.0402 in the past week, and it reached a new high 1 time over the past 12 months. The last 20 days have seen an average of 379,074 shares traded, while the 50-day average volume stands at 357,514.
AXDX stock has decreased by -26.95% in the last month. The company shares reached their 1-month lowest point of $0.4642 on 12/28/22. With the stock rallying to its 52-week high on 01/03/22, shares of the company touched a low of $0.46 and a high of $5.59 in 52 weeks. It has reached a new high 1 time so far this year and lost -87.96% or -$4.6098 in price. In spite of this, the price is down -89.09% from the 52-week high.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
AXDX stock investors should be aware that Accelerate Diagnostics Inc. (AXDX) stock had its last reported insider trading activity 191 days ago on Aug 30. In this transaction, the insider spent $25,660. Chief Executive Officer, Phillips Jack, disposed of 83,708 shares at a price of $0.98 on Apr 28. The insider now owns more than $82,034 worth of shares. Prior to that, Chief Financial Officer REICHLING STEVEN went on to Sale 29,915 shares at $0.98 each on Apr 28. An amount of $29,317 was transacted.
Accelerate Diagnostics Inc. (AXDX) stock’s beta is 1.19. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 4.74.
The quick ratio of Accelerate Diagnostics Inc. for the three months ended September 29 was 6.40, and the current ratio was 6.90, indicating that the company is able to meet its debt obligations. Its gross profit as reported stood at -$0.38 million compared to revenue of $11.78 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Accelerate Diagnostics Inc.’s return on assets was -97.90%.
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$15.71 million in the quarter, while revenues of -$17.8 million were grew 42.78%. The analyst consensus anticipated Accelerate Diagnostics Inc.’s latest quarter earnings to come in at -$0.19 per share, but it turned out to be -$0.18, a 5.30% surprise. For the quarter, EBITDA amounted to -$13.61 million. Shareholders own equity worth $99.1 million.
From a technical analysis perspective, let’s take a brief look at Accelerate Diagnostics Inc. (AXDX) price momentum. RSI 9-day as of the close on 29 December was 42.74%, suggesting the stock is Neutral, with historical volatility in this time frame at 151.90%.
As of today, AXDX’s price is $0.5668 +7.05% or $0.0402 from its 5-day moving average. AXDX is currently trading -26.11% lower than its 20-day SMA and -66.10% lower than its 100-day SMA. However, the stock’s current price level is -61.62% below the SMA50 and -67.88% below the SMA200.
The stochastic %K and %D were 36.45% and 22.35%, respectively, and the average true range (ATR) was 0.0882. With the 14-day stochastic at 46.98% and the average true range at 0.0927, the RSI (14) stands at 37.88%. The stock has reached 0.0028 on the 9-day MACD Oscillator while the 14-day reading was at -0.0344.
Craig Hallum downgraded Accelerate Diagnostics Inc. (NASDAQ: AXDX) to a a Hold rating in its most recent analyst report. Previously, the stock was rated as a Buy. The consensus rating for Accelerate Diagnostics Inc. (AXDX) among analysts is Overweight. According to current brokerage recommendations, 0 brokerage firms advise that investors sell AXDX, while 1 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is AXDX’s price target for the next 12 months?
Analysts predict a range of price targets between $2.00 and $2.00, with a median target of $2.00. Taking a look at these predictions, the average price target given by analysts for Accelerate Diagnostics Inc. (AXDX) stock is $2.00.